Floatz logo

68ga-psma

High Risk

The Methodist Hospital Research InstituteradiopharmaceuticalPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the High Risk cohort.

Asset / SponsorPhaseRating
FILGRASTIM
The First Affiliated Hospital of Soochow University
Phase 4BB
DEXAMETHASONE
The First Affiliated Hospital of Soochow University
Phase 4BB
Bortezomib
The First Affiliated Hospital of Soochow University
Phase 4BB
cc-5013
The First Affiliated Hospital of Soochow University
Phase 4BB
DARATUMUMAB
The First Affiliated Hospital of Soochow University
Phase 4B

View all 17 →

Same molecule, other indications

68ga-psma is also rated in:

prostate cancerDormant
B
Indicative ·
59 / 100
View asset →
metastatic prostate carcinomaDormant
B
Indicative ·
57 / 100
View asset →
prostate adenocarcinomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →